A lot of interesting discussion, Luther, but at the risk of being repetitive I,m sticking with my preferred solution.
Roskamp announces 1st breakthrough in effort to treat Alzheimer's.
IP value of Nilvadipine to treat Alzheimer's goes through the roof.
Roskamp licenses one or more companies to produce and market Nilvadipine to treat Alzheimer's.
Roskamp spins off Archer, and Rock Creek reemerges as a functional corporation.
Archer and Rock Creek merge as equals under the name Archer Rock Creek Health, symbol ARCH, to develop a family of pharmaceuticals based on the Nilvad/Anatabine IP.
